1. Home
  2. HYPD vs RFL Comparison

HYPD vs RFL Comparison

Compare HYPD & RFL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • HYPD
  • RFL
  • Stock Information
  • Founded
  • HYPD 2014
  • RFL 2017
  • Country
  • HYPD United States
  • RFL United States
  • Employees
  • HYPD N/A
  • RFL N/A
  • Industry
  • HYPD
  • RFL Real Estate
  • Sector
  • HYPD
  • RFL Finance
  • Exchange
  • HYPD NYSE
  • RFL Nasdaq
  • Market Cap
  • HYPD 73.3M
  • RFL 74.4M
  • IPO Year
  • HYPD 2018
  • RFL N/A
  • Fundamental
  • Price
  • HYPD $8.26
  • RFL $1.69
  • Analyst Decision
  • HYPD
  • RFL
  • Analyst Count
  • HYPD 0
  • RFL 0
  • Target Price
  • HYPD N/A
  • RFL N/A
  • AVG Volume (30 Days)
  • HYPD 969.8K
  • RFL 200.5K
  • Earning Date
  • HYPD 08-11-2025
  • RFL 06-11-2025
  • Dividend Yield
  • HYPD N/A
  • RFL N/A
  • EPS Growth
  • HYPD N/A
  • RFL N/A
  • EPS
  • HYPD N/A
  • RFL N/A
  • Revenue
  • HYPD $67,063.00
  • RFL $732,000.00
  • Revenue This Year
  • HYPD $7,680.45
  • RFL N/A
  • Revenue Next Year
  • HYPD $315.38
  • RFL N/A
  • P/E Ratio
  • HYPD N/A
  • RFL N/A
  • Revenue Growth
  • HYPD 663.82
  • RFL 35.56
  • 52 Week Low
  • HYPD $0.85
  • RFL $1.28
  • 52 Week High
  • HYPD $112.80
  • RFL $3.19
  • Technical
  • Relative Strength Index (RSI)
  • HYPD N/A
  • RFL 38.88
  • Support Level
  • HYPD N/A
  • RFL $2.03
  • Resistance Level
  • HYPD N/A
  • RFL $2.16
  • Average True Range (ATR)
  • HYPD 0.00
  • RFL 0.15
  • MACD
  • HYPD 0.00
  • RFL -0.05
  • Stochastic Oscillator
  • HYPD 0.00
  • RFL 0.00

About HYPD HYPERION DEFI INC

Hyperion DeFi Inc is a clinical-stage ophthalmic company developing a pipeline of therapeutics based on its proprietary array print (MAP) platform technology. It aims to achieve clinical microdosing of next-generation formulations of novel and existing ophthalmic pharmaceutical agents using its high-precision targeted ocular delivery system, branded the Optejet, which has the potential to replace conventional eye dropper delivery and improve safety, tolerability, patient compliance, and topical delivery success for ophthalmic eye treatments. Using its proprietary delivery technology, Eyenovia is developing the next generation of smart ophthalmic therapies that target new indications or new combinations.

About RFL Rafael Holdings Inc. Class B

Rafael Holdings Inc is a holding company with interests in clinical and early-stage pharmaceutical companies. Its primary focus is to expand its investment portfolio through opportunistic investments including therapeutics, which address high unmet medical needs. Through the companies it has invested in, the company is focused on; developing Trappsol Cyclo its clinical program, developing instruments to advance minimally invasive surgeries, preclinical cancer metabolism research operations, and developing pharmaceutical-grade technology Unlokt for third-party cannabis manufacturers. It also holds and manages commercial real estate assets in Jerusalem, Israel. The company's reportable segments are; Infusion Technology, which derives maximum revenue, Healthcare, and Real Estate.

Share on Social Networks: